{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:18:46Z","timestamp":1793495926362,"version":"4.5.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40263-019-00661-z","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:29:03Z","timestamp":1567250943000},"page":"905-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["Apomorphine for Parkinson\u2019s Disease: Efficacy and Safety of Current and New Formulations"],"prefix":"10.1007","volume":"33","author":[{"given":"Federico","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbin","family":"Djamshidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"issue":"8","key":"661_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm. 2017;124(8):901\u20135.","journal-title":"J Neural Transm."},{"key":"661_CR2","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:17013.","journal-title":"Nat Rev Dis Prim."},{"issue":"11","key":"661_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/jnnp.53.11.1004","volume":"53","author":"PA Kempster","year":"1990","unstructured":"Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1990;53(11):1004\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"661_CR4","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1212\/WNL.36.11.1528","volume":"36","author":"WH Poewe","year":"1986","unstructured":"Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson\u2019s disease: a 6-year follow-up study. Neurology. 1986;36(11):1528\u201330.","journal-title":"Neurology."},{"key":"661_CR5","doi-asserted-by":"crossref","unstructured":"Sweet RD, McDowell FH. Five years\u2019 treatment of Parkinson\u2019s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med. 1975;83(4):456\u201363.","DOI":"10.7326\/0003-4819-83-4-456"},{"issue":"1","key":"661_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0378-8741(81)90013-1","volume":"3","author":"WA Emboden","year":"1981","unstructured":"Emboden WA. Transcultural use of narcotic water lilies in ancient egyptian and maya drug ritual. J Ethnopharmacol. 1981;3(1):39\u201383.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"661_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0378-8741(82)90039-3","volume":"5","author":"WA Emboden","year":"1982","unstructured":"Emboden WA. The mushroom and the water lily: literary and pictorial evidence for Nymphaea as a ritual psychotogen in mesoamerica. J Ethnopharmacol. 1982;5(2):139\u201348.","journal-title":"J Ethnopharmacol"},{"issue":"2","key":"661_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/014107680409700214","volume":"97","author":"E Bertol","year":"2004","unstructured":"Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I. Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology. J R Soc Med. 2004;97(2):84\u20135.","journal-title":"J R Soc Med"},{"key":"661_CR9","first-page":"455","volume":"17","author":"A Matthiessen","year":"1868","unstructured":"Matthiessen A, Wright CRA. Researches into the Chemical constitution of the opium bases. Part I. on the action of hydrochloric acid on morphia. Proc R Soc Lond. 1868;17:455\u201360 (6 pages).","journal-title":"Proc R Soc Lond."},{"issue":"1","key":"661_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/jlac.18450550107","volume":"55","author":"AE Arppe","year":"1845","unstructured":"Arppe AE. Ueber eine merkw\u00fcrdige Ver\u00e4nderung des Morphins durch Schwefels\u00e4ure. Ann der Chemie und Pharm. 1845;55(1):96\u2013101.","journal-title":"Ann der Chemie und Pharm."},{"issue":"6","key":"661_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000346762","volume":"69","author":"P Taba","year":"2013","unstructured":"Taba P, Lees A, Stern G. Erich Harnack (1852-1915) and a short history of apomorphine. Eur Neurol. 2013;69(6):321\u20134.","journal-title":"Eur Neurol"},{"issue":"478","key":"661_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/bmj.1.478.204","volume":"1","author":"FM Pierce","year":"1870","unstructured":"Pierce FM. Notes on Apomorphia. BMJ. 1870;1(478):204.","journal-title":"BMJ"},{"key":"661_CR13","volume-title":"On alcoholism its clinical aspects and treatment","author":"F Hare","year":"1912","unstructured":"Hare F. On alcoholism its clinical aspects and treatment. London: J&A Churchill; 1912."},{"key":"661_CR14","first-page":"166","volume":"2","author":"S Gee","year":"1869","unstructured":"Gee S. On the action of a new organic base, apomorphia. Clin Soc Trans. 1869;2:166\u20139.","journal-title":"Clin Soc Trans."},{"key":"661_CR15","unstructured":"Siebert V: Untersuchungen \u00fcber die physiologischen Wirkungen des Apomorphin. Inaugural-Dissertation zur Erlangung der Doctorgrades. Dorpat, Druck von Heinrich Laakmann, 1871."},{"issue":"2\u20134","key":"661_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0005-7967(63)90042-1","volume":"1","author":"MJ Raymond","year":"1963","unstructured":"Raymond MJ. The treatment of addiction by avversive conditioning with apomorphine. Behav Res Ther. 1963;1(2\u20134):287\u201391.","journal-title":"Behav Res Ther"},{"key":"661_CR17","doi-asserted-by":"crossref","unstructured":"Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry. 1991;358\u201360.","DOI":"10.1136\/jnnp.54.4.358"},{"issue":"8582","key":"661_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(88)91193-2","volume":"331","author":"CMH Stibe","year":"1988","unstructured":"Stibe CMH, Kempster PA, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet. 1988;331(8582):403\u20136.","journal-title":"Lancet"},{"issue":"3","key":"661_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1360-0443.1987.tb01479.x","volume":"82","author":"F Lemere","year":"1987","unstructured":"Lemere F. Aversion treatment of alcoholism: some reminiscences. Addiction. 1987;82(3):257\u20138.","journal-title":"Addiction"},{"issue":"2","key":"661_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1517\/13543784.11.2.295","volume":"11","author":"JP Mulhall","year":"2002","unstructured":"Mulhall JP. Sublingual apomorphine for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002;11(2):295\u2013302.","journal-title":"Expert Opin Investig Drugs"},{"key":"661_CR21","first-page":"411","volume":"47","author":"E De Weill","year":"1884","unstructured":"De Weill E. l\u2019apomorphine dans certains troubles nerveux. Lyon Med. 1884;47:411\u20138.","journal-title":"Lyon Med."},{"key":"661_CR22","first-page":"251","volume":"56","author":"RS Schwab","year":"1951","unstructured":"Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson\u2019s disease. Trans Am Neurol Assoc. 1951;56:251\u20133.","journal-title":"Trans Am Neurol Assoc."},{"issue":"1\u20132","key":"661_CR23","first-page":"46","volume":"152","author":"A Struppler","year":"1953","unstructured":"Struppler A, Von Uexkull T. Studies of mechanism of action of apormorphine on Parkinson\u2019s tremor. Z Klin Med. 1953;152(1\u20132):46\u201357.","journal-title":"Z Klin Med."},{"issue":"13","key":"661_CR24","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.1971.03190260019005","volume":"218","author":"GC Cotzias","year":"1971","unstructured":"Cotzias GC. Levodopa in the treatment of Parkinsonism. JAMA. 1971;218(13):1903\u20138.","journal-title":"JAMA"},{"issue":"4","key":"661_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969;21(4):343\u201354.","journal-title":"Arch Neurol"},{"issue":"1","key":"661_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJM197001012820107","volume":"282","author":"GC Cotzias","year":"1970","unstructured":"Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med. 1970;282(1):31\u20133.","journal-title":"N Engl J Med"},{"issue":"8123","key":"661_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0140-6736(79)91725-2","volume":"1","author":"GU Corsini","year":"1979","unstructured":"Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson\u2019s disease. Lancet (London, England). 1979;1(8123):954\u20136.","journal-title":"Lancet (London, England)."},{"issue":"8537","key":"661_CR28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(87)91660-6","volume":"329","author":"C Stibe","year":"1987","unstructured":"Stibe C, Lees A, Stern G. Subcutaneous Infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987;329(8537):871.","journal-title":"Lancet"},{"issue":"12","key":"661_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/BF01897450","volume":"22","author":"AM Ernst","year":"1966","unstructured":"Ernst AM, Smelik PG. Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats. Experientia. 1966;22(12):837\u20138.","journal-title":"Experientia"},{"issue":"4","key":"661_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40261-018-0619-3","volume":"38","author":"M Auffret","year":"2018","unstructured":"Auffret M, Drapier S, V\u00e9rin M. Pharmacological insights into the use of apomorphine in parkinson\u2019s disease: clinical relevance. Clin Drug Investig. 2018;38(4):287\u2013312.","journal-title":"Clin Drug Investig."},{"key":"661_CR31","doi-asserted-by":"crossref","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J-A, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791\u2013804.","DOI":"10.1124\/jpet.102.039867"},{"key":"661_CR32","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2016.12.003","volume":"33","author":"P Jenner","year":"2016","unstructured":"Jenner P, Katzenschlager R. Apomorphine\u2014pharmacological properties and clinical trials in Parkinson\u2019s disease. Park Relat Disord. 2016;33:S13\u201321.","journal-title":"Park Relat Disord."},{"issue":"2","key":"661_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/WNF.0b013e31816d91f9","volume":"32","author":"PA LeWitt","year":"2009","unstructured":"LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating \u2018off\u2019 episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009;32(2):89\u201393.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"661_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mds.870060304","volume":"6","author":"ST Gancher","year":"1991","unstructured":"Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord. 1991;6(3):212\u20136.","journal-title":"Mov Disord"},{"issue":"5","key":"661_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1472-8206.1993.tb00238.x","volume":"7","author":"E Nicolle","year":"1993","unstructured":"Nicolle E, Pollak P, Serre-Debeauvais F, Richard P, Gervason CL, Broussolle E, et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol. 1993;7(5):245\u201352.","journal-title":"Fundam Clin Pharmacol"},{"issue":"Pt 2","key":"661_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/brain\/124.2.331","volume":"124","author":"AJ Manson","year":"2001","unstructured":"Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson\u2019s disease: clinical and pharmacokinetic observations. Brain. 2001;124(Pt 2):331\u201340.","journal-title":"Brain"},{"issue":"16","key":"661_CR37","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1517\/14656566.8.16.2799","volume":"8","author":"IU Haq","year":"2007","unstructured":"Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson\u2019s disease: a review. Expert Opin Pharmacother. 2007;8(16):2799\u2013809.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"661_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/ana.410260209","volume":"26","author":"ST Gancher","year":"1989","unstructured":"Gancher ST, Woodward WR, Boucher SB, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol. 1989;26(2):232\u20138.","journal-title":"Ann Neurol"},{"issue":"3","key":"661_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/106002809502900310","volume":"29","author":"DL Corboy","year":"1995","unstructured":"Corboy DL, Wagner ML, Sage JI. Apomorphine for motor fluctuations and freezing in Parkinson\u2019s disease. Ann Pharmacother. 1995;29(3):282\u20138.","journal-title":"Ann Pharmacother"},{"issue":"6 Suppl 4","key":"661_CR40","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1212\/WNL.62.6_suppl_4.S8","volume":"62","author":"PA LeWitt","year":"2004","unstructured":"LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl 4):S8\u201311.","journal-title":"Neurology."},{"issue":"6","key":"661_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WNF.0000000000000111","volume":"38","author":"M Nomoto","year":"2015","unstructured":"Nomoto M, Kubo SI, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38(6):241\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"661_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","volume":"4","author":"S Isaacson","year":"2016","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson\u2019s disease. Mov Disord Clin Pract. 2016;4(1):78\u201383.","journal-title":"Mov Disord Clin Pract."},{"issue":"2","key":"661_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00002826-199304000-00003","volume":"16","author":"CL Gervason","year":"1993","unstructured":"Gervason CL, Pollak PR, Limousin P, Perret JE. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson\u2019s disease. Clin Neuropharmacol. 1993;16(2):113\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"661_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00002826-199106000-00003","volume":"14","author":"AJ Hughes","year":"1991","unstructured":"Hughes AJ, Bishop S, Stern GM, Lees AJ. The motor response to repeated apomorphine administration in Parkinson\u2019s disease. Clin Neuropharmacol. 1991;14(3):209\u201313.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"661_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359.","journal-title":"Lancet Neurol."},{"issue":"2","key":"661_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/jnnp.53.2.96","volume":"53","author":"JP Frankel","year":"1990","unstructured":"Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96\u2013101.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"661_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","volume":"65","author":"K Pietz","year":"1998","unstructured":"Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson\u2019s disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709\u201316.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"661_CR48","unstructured":"Wenning GK1, B\u00f6sch S, Luginger E, Wagner M PW. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson\u2019s disease. PubMed NCBI. Adv Neurol. 1999;(80):545\u20138."},{"issue":"2","key":"661_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00002826-199704000-00008","volume":"20","author":"M Merello","year":"2006","unstructured":"Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson\u02bcs disease patients. Clin Neuropharmacol. 2006;20(2):165\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"661_CR50","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/mds.870130505","volume":"13","author":"RB Dewey","year":"1998","unstructured":"Dewey RB, Maraganore D, Ahlskog JE, Matsumoto J. A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson\u2019s disease. Mov Disord. 1998;13(5):782\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"661_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14802\/jmd.09002","volume":"2","author":"A Antonini","year":"2009","unstructured":"Antonini A. Apomorphine and levodopa infusion therapies for advanced Parkinson\u2019s disease. J Mov Disord. 2009;2(1):4\u20139.","journal-title":"J Mov Disord."},{"key":"661_CR52","first-page":"S146","volume":"20","author":"J Anthony","year":"2005","unstructured":"Anthony J, Spears J, Van Lunen B. Implications of motor fluctuations in Parkinson\u2019s disease patients on chronic therapy (IMPACT): results from an observational registry. Mov Disord. 2005;20:S146.","journal-title":"Mov Disord"},{"issue":"3\u20134","key":"661_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1472-8206.1993.tb00226.x","volume":"7","author":"A Lees","year":"1993","unstructured":"Lees A. Dopamine agonists in Parkinson\u2019s disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3\u20134):121\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"9","key":"661_CR54","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2003","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A Randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol. 2003;58(9):1385.","journal-title":"Arch Neurol"},{"issue":"2","key":"661_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archneurol.2007.58","volume":"65","author":"SA Gunzler","year":"2008","unstructured":"Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol. 2008;65(2):193\u20138.","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"661_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","volume":"258","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Koller WC, Trosch RM, Sherry JH. Subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258(1\u20132):137\u201343.","journal-title":"J Neurol Sci"},{"key":"661_CR57","unstructured":"Canadian Agency for Drugs. Clinical Review Report: Apomorphine (Movapo): (Paladin Labs Inc.): Indication: The acute, intermittent treatment of hypomobility \u201coff\u201d episodes (\u201cend-of-dose wearing off\u201d and unpredictable \u201con\/off\u201d episodes) in patients with advanced Parkinson\u2019s disease. CADTH Common Drug Reviews. 2018."},{"issue":"12","key":"661_CR58","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41582-018-0083-y","volume":"14","author":"A Antonini","year":"2018","unstructured":"Antonini A, Jenner P. Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol. 2018;14(12):693\u20134.","journal-title":"Nat Rev Neurol."},{"issue":"8","key":"661_CR59","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","volume":"125","author":"A Antonini","year":"2018","unstructured":"Antonini A, Nitu B. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm. 2018;125(8):1131\u20135.","journal-title":"J Neural Transm."},{"issue":"3","key":"661_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-019-09184-5","volume":"266","author":"\u00c1 Sesar","year":"2019","unstructured":"Sesar \u00c1, Fern\u00e1ndez-Pajar\u00edn G, Ares B, Relova JL, Ar\u00e1n E, Rivas MT, et al. Continuous subcutaneous apomorphine in advanced Parkinson\u2019s disease patients treated with deep brain stimulation. J Neurol. 2019;266(3):659\u201366.","journal-title":"J Neurol"},{"key":"661_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.09.025","volume":"45","author":"RWK Borgemeester","year":"2017","unstructured":"Borgemeester RWK, van Laar T. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease patients with cognitive dysfunction: a retrospective long-term follow-up study. Park Relat Disord. 2017;45:33\u20138.","journal-title":"Park Relat Disord."},{"issue":"8","key":"661_CR62","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/mds.22063","volume":"23","author":"PJ Garc\u00eda Ruiz","year":"2008","unstructured":"Garc\u00eda Ruiz PJ, Sesar Ignacio \u00c1, Ares Pensado B, Castro Garc\u00eda A, Alonso Frech F, \u00c1lvarez L\u00f3pez M, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130\u20136.","journal-title":"Mov Disord"},{"key":"661_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","volume":"23","author":"RWK Borgemeester","year":"2016","unstructured":"Borgemeester RWK, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson\u2019s disease patients. Park Relat Disord. 2016;23:17\u201322.","journal-title":"Park Relat Disord."},{"key":"661_CR64","doi-asserted-by":"crossref","unstructured":"Todorova A, Ray Chaudhuri K. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson\u2019s disease. Park Dis Curr Futur Ther Clin Trials. 2016;48\u201362.","DOI":"10.1017\/CBO9781107284210.006"},{"issue":"2","key":"661_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151\u20137.","journal-title":"Mov Disord"},{"issue":"2","key":"661_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol."},{"issue":"6","key":"661_CR67","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/mds.10281","volume":"17","author":"AJ Manson","year":"2002","unstructured":"Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson\u2019s disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17(6):1235\u201341.","journal-title":"Mov Disord"},{"key":"661_CR68","doi-asserted-by":"crossref","unstructured":"Katunina E, Titova N. The Epidemiology of Nonmotor Symptoms in Parkinson\u2019s Disease (Cohort and Other Studies). In: International review of neurobiology. 2017. pp. 91\u2013110.","DOI":"10.1016\/bs.irn.2017.05.012"},{"issue":"2","key":"661_CR69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","volume":"1","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197\u2013203.","journal-title":"J Parkinsons Dis."},{"issue":"4","key":"661_CR70","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord. 2015;30(4):510\u20136.","journal-title":"Mov Disord"},{"key":"661_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","volume":"27","author":"RWK Borgemeester","year":"2016","unstructured":"Borgemeester RWK, Lees AJ, van Laar T. Parkinson\u2019s disease, visual hallucinations and apomorphine: a review of the available evidence. Park Relat Disord. 2016;27:35\u201340.","journal-title":"Park Relat Disord."},{"key":"661_CR72","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.parkreldis.2016.11.020","volume":"33","author":"M Rosa-Grilo","year":"2016","unstructured":"Rosa-Grilo M, Qamar MA, Evans A, Chaudhuri KR. The efficacy of apomorphine\u2014a non-motor perspective. Park Relat Disord. 2016;33:S28\u201335.","journal-title":"Park Relat Disord."},{"issue":"2","key":"661_CR73","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","volume":"3","author":"C Ellis","year":"1997","unstructured":"Ellis C, Lemmens G, Parkes JD, Abbott RJ, Pye IF, Leigh PN, et al. Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Park Relat Disord. 1997;3(2):103\u20137.","journal-title":"Park Relat Disord."},{"issue":"12","key":"661_CR74","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930.","journal-title":"JAMA Intern Med."},{"issue":"3","key":"661_CR75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mdc3.12416","volume":"4","author":"P Barbosa","year":"2016","unstructured":"Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in parkinson\u2019s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract. 2016;4(3):323\u20138.","journal-title":"Mov Disord Clin Pract."},{"issue":"2","key":"661_CR76","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/mds.26099","volume":"30","author":"M Samuel","year":"2015","unstructured":"Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie J, Ray Chaudhuri K, Brown R, et al. Impulse control disorders in parkinson\u2019s disease: management, controversies, and potential approaches HHS public access. Mov Disord. 2015;30(2):150\u20139.","journal-title":"Mov Disord"},{"issue":"2","key":"661_CR77","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.22319","volume":"69","author":"E Himeno","year":"2011","unstructured":"Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N, et al. Apomorphine treatment in Alzheimer mice promoting amyloid-\u03b2 degradation. Ann Neurol. 2011;69(2):248\u201356.","journal-title":"Ann Neurol"},{"issue":"5","key":"661_CR78","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.26422","volume":"31","author":"AJ Yarnall","year":"2016","unstructured":"Yarnall AJ, Lashley T, Ling H, Lees AJ, Coleman SY, O\u2019Sullivan SS, et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson\u2019s disease? Mov Disord. 2016;31(5):668\u201375.","journal-title":"Mov Disord"},{"issue":"11","key":"661_CR79","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00002512-200421110-00001","volume":"21","author":"D Deleu","year":"2004","unstructured":"Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson\u2019s disease. Drugs Aging. 2004;21(11):687\u2013709.","journal-title":"Drugs Aging"},{"issue":"1","key":"661_CR80","first-page":"58","volume":"54","author":"R Loewe","year":"2003","unstructured":"Loewe R, P\u00fcsp\u00f6k-Schwarz M, Petzelbauer P. Apomorphin-pigmentierung. Der Hautarzt. 2003;54(1):58\u201363.","journal-title":"Der Hautarzt."},{"issue":"3","key":"661_CR81","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1046\/j.1365-2133.1998.02128.x","volume":"138","author":"KM Acland","year":"1998","unstructured":"Acland KM, Churchyard A, Fletcher CL, Turner K, Lees A, Dowd PM. Panniculitis in association with apomorphine infusion. Br J Dermatol. 1998;138(3):480\u20132.","journal-title":"Br J Dermatol"},{"issue":"1","key":"661_CR82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mdc3.12425","volume":"4","author":"M Skorvanek","year":"2017","unstructured":"Skorvanek M, Bhatia KP. The skin and Parkinson\u2019s disease: review of clinical, diagnostic, and therapeutic issues. Mov Disord Clin Pract. 2017;4(1):21\u201331.","journal-title":"Mov Disord Clin Pract."},{"issue":"3","key":"661_CR83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mdc3.12416","volume":"4","author":"P Barbosa","year":"2017","unstructured":"Barbosa P, Lees AJ, Magee C, Djamshidian A, Warner TT. A retrospective evaluation of the frequency of impulsive compulsive behaviors in Parkinson\u2019s disease patients treated with continuous waking day apomorphine pumps. Mov Disord Clin Pract. 2017;4(3):323\u20138.","journal-title":"Mov Disord Clin Pract."},{"key":"661_CR84","unstructured":"A. Todorova, A. Martin, D. Okai, M.Samuel, R. Brown, A. David KRC. Assessment of impulse control disorders in Parkinson\u2019s patients with infusion therapies: a single centre experience. Mov Disord. 2013;28(Suppl. 1):366."},{"issue":"1","key":"661_CR85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mdc3.12373","volume":"4","author":"B Venegas P\u00e9rez","year":"2017","unstructured":"Venegas P\u00e9rez B, Arquero Portero T, S\u00e1nchez Fern\u00e1ndez MS, Feliz Feliz C, Del Val Fern\u00e1ndez J, Garc\u00eda-Ruiz PJ. Apomorphine-induced immune hemolytic anemia. Mov Disord Clin Pract. 2017;4(1):145\u20137.","journal-title":"Mov Disord Clin Pract."},{"key":"661_CR86","doi-asserted-by":"crossref","unstructured":"Renoux C, Dell\u2019Aniello S, Khairy P, Marras C, Bugden S, Turin TC, et al. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson\u2019s disease. Br J Clin Pharmacol. 2016;461\u2013472.","DOI":"10.1111\/bcp.12964"},{"issue":"2","key":"661_CR87","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11096-019-00803-9","volume":"41","author":"K Y\u00fcksel","year":"2019","unstructured":"Y\u00fcksel K, Tu\u011flular I. Critical review of European Medicines Agency (EMA) assessment report and related literature on domperidone. Int J Clin Pharm. 2019;41(2):387\u201390.","journal-title":"Int J Clin Pharm."},{"issue":"3","key":"661_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0000000000000082","volume":"38","author":"R Bhidayasiri","year":"2015","unstructured":"Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T. Effective delivery of apomorphine in the management of Parkinson disease. Clin Neuropharmacol. 2015;38(3):1.","journal-title":"Clin Neuropharmacol"},{"key":"661_CR89","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.parkreldis.2016.11.016","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Sringean J, Anan C, Boonpang K, Thanawattano C, Ray Chaudhuri K. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson\u2019s disease using wearable sensors. Park Relat Disord. 2016;33:S36\u201341.","journal-title":"Park Relat Disord."},{"issue":"9","key":"661_CR90","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","volume":"21","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Garc\u00eda Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-D\u00f6ring F, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson\u2019s disease\u2014clinical practice recommendations. Park Relat Disord. 2015;21(9):1023\u201330.","journal-title":"Park Relat Disord."},{"issue":"11","key":"661_CR91","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/ene.12091","volume":"20","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing \u2018off\u2019 periods in patients with established Parkinson\u2019s disease. Eur J Neurol. 2013;20(11):1445\u201350.","journal-title":"Eur J Neurol"},{"issue":"3","key":"661_CR92","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/ane.12107","volume":"128","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled dry powder apomorphine (VR040) for\u2019off\u2019 periods in Parkinson\u2019s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013;128(3):166\u201371.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"661_CR93","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JPD-120142","volume":"3","author":"KA Grosset","year":"2013","unstructured":"Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled apomorphine in patients with \u2018on-off\u2019 fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study. J Parkinsons Dis. 2013;3(1):31\u20137.","journal-title":"J Parkinsons Dis."},{"issue":"9","key":"661_CR94","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/jphp.12758","volume":"69","author":"N Borkar","year":"2017","unstructured":"Borkar N, Andersson DR, Yang M, M\u00fcllertz A, Holm R, Mu H. Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson\u2019s disease rat model. J Pharm Pharmacol. 2017;69(9):1110\u20135.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"661_CR95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1464-4096.2001.00124.x","volume":"88","author":"A Argiolas","year":"2001","unstructured":"Argiolas A, Hedlund H. The pharmacology and clinical pharmacokinetics of apomorphine SL. BJU Int Suppl. 2001;88(3):18\u201321.","journal-title":"BJU Int Suppl."},{"key":"661_CR96","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/j.parkreldis.2017.11.285","volume":"46","author":"HH Fernandez","year":"2018","unstructured":"Fernandez HH, Isaacson S, Espay AJ, Pahwa R, Truong D, Pappert E, et al. Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson\u2019s disease: preliminary results from the Phase-3 study dose titration phase. Parkinsonism Relat Disord. 2018;46:e82.","journal-title":"Parkinsonism Relat Disord."},{"issue":"12","key":"661_CR97","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/jnnp.52.12.1440","volume":"52","author":"AJ Lees","year":"1989","unstructured":"Lees AJ, Montastruc JL, Turjanski N, Rascol O, Kleedorfer B, Peyro Saint-Paul H, et al. Sublingual apomorphine and Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1989;52(12):1440.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"661_CR98","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.26697","volume":"31","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson\u2019s disease. Mov Disord. 2016;31(9):1366\u201372.","journal-title":"Mov Disord"},{"key":"661_CR99","doi-asserted-by":"crossref","unstructured":"Factor SA, Isaacson S, Hauser RA et al. Efficacy and safety of apomorphine sublingual film for the treatment of \u2018OFF\u2019 episodes in patients with Parkinson\u2019s disease: phase 3, double blind placebo-controlled trail. 2019.","DOI":"10.1212\/WNL.92.15_supplement.P2.8-053"},{"key":"661_CR100","doi-asserted-by":"crossref","unstructured":"Shaltiel-Karyo R, Tsarfati Y, Zawoznik E, Weinstock I, Nemas M, Rubinski A, Schiffenbauer Y, Nyska A, Yacoby-Zeevi O. ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump (P4.006). Neurology. 2107. 88 (16 Sup):P4.006.","DOI":"10.1212\/WNL.88.16_supplement.P4.006"},{"issue":"5","key":"661_CR101","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40263-018-0512-x","volume":"32","author":"Y Ramot","year":"2018","unstructured":"Ramot Y, Nyska A, Adar L, Durlach C, Fishelovitch D, Sacco G, et al. ND0701, A novel formulation of apomorphine for subcutaneous infusion, in comparison to a commercial apomorphine formulation: 28-day pharmacokinetic study in minipigs and a phase I study in healthy volunteers to assess the safety, tolerability, npharmacokinetics and relative bioavailability. CNS Drugs. 2018;32(5):443\u201354.","journal-title":"CNS Drugs"},{"issue":"3","key":"661_CR102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/s-2007-1020585","volume":"16","author":"W Poewe","year":"1989","unstructured":"Poewe W, Kleedorfer B, Gerstenbrand F, Oertel WH. Die Behandlung von Parkinsonpatienten mit L-Dopa\u2014Wirkungsfluktuation mittels subkutanen Apomorphingaben. Aktuelle Neurol. 1989;16(3):73\u20137.","journal-title":"Aktuelle Neurol."},{"issue":"8646","key":"661_CR103","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(89)92487-2","volume":"333","author":"W Poewe","year":"1989","unstructured":"Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W. Side-effects of subcutaneous apomorphine in Parkinson\u2019s disease. Lancet. 1989;333(8646):1084\u20135.","journal-title":"Lancet"},{"issue":"2","key":"661_CR104","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mds.870080208","volume":"8","author":"AJ Hughes","year":"1993","unstructured":"Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, et al. Subcutaneous apomorphine in parkinson\u2019s disease: response to chronic administration for up to five years. Mov Disord. 1993;8(2):165\u201370.","journal-title":"Mov Disord"},{"issue":"3","key":"661_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00002826-199706000-00009","volume":"20","author":"J Esteban Mu\u00f1oz","year":"1997","unstructured":"Esteban Mu\u00f1oz J, Mart\u00ed MJ, Mar\u00edn C, Tolosa E. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol. 1997;20(3):245\u201352.","journal-title":"Clin Neuropharmacol"},{"key":"661_CR106","doi-asserted-by":"crossref","unstructured":"Van Laar T, Jansen ENH, Essink A, Neef C, S. O, van Laar T, et al. A double-blind study of the efficacy of apomorphine and its assessment in \u2018off\u2019-periods in Parkinson\u2019s disease. Clin Neurol Neurosurg. 1993;95(3):231\u2013235.","DOI":"10.1016\/0303-8467(93)90128-4"},{"issue":"6","key":"661_CR107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/jnnp.58.6.681","volume":"58","author":"L Ostergaard","year":"1995","unstructured":"Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, et al. Pen injected apomorphine against off phenomena in late Parkinson\u2019s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;58(6):681\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"661_CR108","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","volume":"13","author":"RF Pfeiffer","year":"2007","unstructured":"Pfeiffer RF, Gutmann L, Hull KL, Bottini PB, Sherry JH. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease. Park Relat Disord. 2007;13(2):93\u2013100.","journal-title":"Park Relat Disord."},{"issue":"8","key":"661_CR109","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.parkreldis.2014.04.008","volume":"20","author":"N Hattori","year":"2014","unstructured":"Hattori N, Nomoto M, Kimura T, Kikuchi S, Enomoto H, Yoshizawa K, et al. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson\u2019s disease. Park Relat Disord. 2014;20(8):819\u201323.","journal-title":"Park Relat Disord."},{"key":"661_CR110","unstructured":"PharmaPendium, Post-marketing reports (AERS) for apomorphine hydrochloride and cardiac disorders. https:\/\/www.pharmapendium.com\/postmarket.do?initial.drug%5B0%5D=Apomorphine+Hydrochloride&strcture=false&multiView.statEntityType=EFFECT&chemistry=false&initial.effect&5B0%5D=Cardiac+disorders&multiView.entityType=DRUG ."},{"issue":"6","key":"661_CR111","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bcpt.12343","volume":"116","author":"Y Watanabe","year":"2015","unstructured":"Watanabe Y, Nakamura Y, Cao X, Ohara H, Yamazaki Y, Murayama N, Sugiyama Y, Izumi-Nakaseko H, Ando K, Yamazaki H, Sugiyama A. Intravenous Administration of Apomorphine Does NOT Induce Long QT Syndrome: Experimental Evidence from Canine Models. Basic Clin Pharmacol Toxicol. 2015;116(6):468\u201375.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"661_CR112","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s100720170062","volume":"22","author":"F Stocchi","year":"2001","unstructured":"Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci. 2001;22(1):93\u20134.","journal-title":"Neurol Sci"},{"issue":"11","key":"661_CR113","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","volume":"251","author":"HL Tyne","year":"2004","unstructured":"Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson\u2019s disease. J Neurol. 2004;251(11):1370\u20134.","journal-title":"J Neurol"},{"issue":"1","key":"661_CR114","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2011.08.010","volume":"18","author":"S Drapier","year":"2012","unstructured":"Drapier S, Gillioz A-N, Leray E, P\u00e9ron J, Rouaud T, Marchand A, V\u00e9rin M. Apomorphine infusion in advanced Parkinson\u2019s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord. 2012;18(1):40\u20134.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"661_CR115","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/imj.13378","volume":"47","author":"TE Kimber","year":"2017","unstructured":"Kimber TE, Fang J, Huddy LJ, Thompson PD. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Int Med J. 2017;47(5):570\u20133.","journal-title":"Int Med J"},{"issue":"3","key":"661_CR116","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neurol.2013.10.012","volume":"170","author":"M Rambour","year":"2014","unstructured":"Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Dest\u00e9e A, Defebvre L. Le traitement par apomorphine en perfusion continue sous-cutan\u00e9e dans la maladie de Parkinson: analyse r\u00e9trospective d\u2019une s\u00e9rie de 81 patients. Revue Neurologique. 2014;170(3):205\u201315.","journal-title":"Revue Neurologique"},{"issue":"6","key":"661_CR117","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","volume":"263","author":"S Drapier","year":"2016","unstructured":"Drapier S, Eusebio A, Degos B, V\u00e9rin M, Durif F, Azulay JP, Viallet F, Rouaud T, Moreau C, Defebvre L, Fraix V, Tranchant C, Andre K, Courbon CB, Roze E, Devos D. Quality of life in Parkinson\u2019s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol. 2016;263(6):1111\u20139.","journal-title":"J Neurol"},{"issue":"5","key":"661_CR118","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","volume":"264","author":"A Sesar","year":"2017","unstructured":"Sesar A, Fern\u00e1ndez-Pajar\u00edn G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion inadvanced Parkinson\u2019s disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946\u201354.","journal-title":"J Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-019-00661-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00661-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T20:46:58Z","timestamp":1721681218000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-019-00661-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":118,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00661-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"31 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript. Open access funding provided by University of Innsbruck and Medical University of Innsbruck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Federico Carbone has no conflicts of interest that are directly relevant to the content of this review. Atbin Djamshidian has received consulting fees from Abbvie and Gr\u00fcnenthal. Klaus Seppi has received fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceutical AG, Roche, Gr\u00fcnenthal and Abbvie; honoraria and research grants from the International Parkinson and Movement Disorder Society; and research grants from the FWF Austrian Science Fund and Micheal J. Fox Foundation outside of the submitted work. Werner Poewe has received consulting fees from Britannia Pharmaceuticals for planning and implementation of the TOLEDO study; consulting fees from Gr\u00fcnenthal in relation to apomorphine educational activities; and lecture fees from Britannia Pharmaceuticals and Gr\u00fcnenthal related to symposia on the TOLEDO study and for apomorphine educational activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}